These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28463874)

  • 21. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.
    Pickar JH; Mirkin S
    Menopause Int; 2010 Sep; 16(3):121-8. PubMed ID: 20956688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss.
    Komm BS; Mirkin S; Jenkins SN
    Steroids; 2014 Nov; 90():71-81. PubMed ID: 24929044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial.
    Bachmann G; Crosby U; Feldman RA; Ronkin S; Constantine GD
    Menopause; 2011 May; 18(5):508-14. PubMed ID: 21289525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Timing and persistence of effect of conjugated estrogens/bazedoxifene in postmenopausal women.
    Kagan R; Komm BS; Ryan KA; Lavenberg J; Yu CR; Pinkerton JV
    Menopause; 2016 Nov; 23(11):1204-1213. PubMed ID: 27433860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conjugated estrogen/bazedoxifene tablets for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.
    Mirkin S; Komm B; Pickar JH
    Womens Health (Lond); 2014 Mar; 10(2):135-46. PubMed ID: 24601804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms.
    Kagan R
    J Womens Health (Larchmt); 2012 Sep; 21(9):975-81. PubMed ID: 22759213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
    Bachmann G; Bobula J; Mirkin S
    Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ospemifene's effect on vasomotor symptoms: a post hoc analysis of phase 2 and 3 clinical data.
    Constantine GD; Archer DF; Pollycove R; Jiang W; Altomare C; Pinkerton JV
    Menopause; 2016 Sep; 23(9):957-64. PubMed ID: 27404027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.
    Gordon S; Walsh BW; Ciaccia AV; Siddhanti S; Rosen AS; Plouffe L
    Obstet Gynecol; 2004 Feb; 103(2):267-73. PubMed ID: 14754694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women.
    Pinkerton JV; Stovall DW
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1613-21. PubMed ID: 21073353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene.
    Abraham L; Pinkerton JV; Messig M; Ryan KA; Komm BS; Mirkin S
    Maturitas; 2014 Jul; 78(3):212-8. PubMed ID: 24837362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial investigation into the optimal dose ratio of conjugated estrogens and bazedoxifene: a double-blind, randomized, placebo-controlled phase 2 dose-finding study.
    Pickar JH; Lavenberg J; Pan K; Komm BS
    Menopause; 2018 Mar; 25(3):273-285. PubMed ID: 29088019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of conjugated estrogens/bazedoxifene on lipid and coagulation variables: a randomized placebo- and active-controlled trial.
    Skouby SO; Pan K; Thompson JR; Komm BS; Mirkin S
    Menopause; 2015 Jun; 22(6):640-9. PubMed ID: 25405570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthetic conjugated estrogens-B and postmenopausal nocturnal vasomotor symptoms: a randomized controlled trial.
    Liu JH; Reape KZ; Hait HI
    Obstet Gynecol; 2012 Jan; 119(1):78-84. PubMed ID: 22183214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
    Pickar JH; Komm BS
    Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
    Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
    Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial.
    Reddy SY; Warner H; Guttuso T; Messing S; DiGrazio W; Thornburg L; Guzick DS
    Obstet Gynecol; 2006 Jul; 108(1):41-8. PubMed ID: 16816054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the measurement model and clinically important differences for menopause-specific quality of life associated with bazedoxifene/conjugated estrogens.
    Bushmakin AG; Abraham L; Pinkerton JV; Cappelleri JC; Mirkin S
    Menopause; 2014 Aug; 21(8):815-22. PubMed ID: 24378765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms.
    Mirkin S; Ryan KA; Chandran AB; Komm BS
    Maturitas; 2014 Jan; 77(1):24-31. PubMed ID: 24246155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.
    Pinkerton JV; Pickar JH; Racketa J; Mirkin S
    Climacteric; 2012 Oct; 15(5):411-8. PubMed ID: 22853444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.